Mary Reilly
Has grant
Professor of Clinical Neurology and Consultant Neurologist
Research Interests
Explore related searches
Contact this professor
Get a free first email built on one of their papers, ready for you to edit and send yourself.
About
Mary Reilly is a Professor of Clinical Neurology and Consultant Neurologist at The National Hospital for Neurology and Neurosurgery in the UK. Her research primarily focuses on peripheral neuropathies, including hereditary transthyretin-mediated amyloidosis and Charcot-Marie-Tooth disease. Recent publications highlight her work on the clinical characteristics and genetic factors associated with these conditions, as well as the importance of early diagnosis in treating TTR amyloidosis.
Recent Grants
Grant: Close
• CMTA Hereditary Sensory Neuropathy Serine trial (SENSE trial)
Open Date: 2022-03-01
Close Date: 2025-02-01
Grant: Close
Preventable axon degeneration in human disease G
Open Date: 2021-10-01
Close Date: 2026-09-01
Grant: Close
NIH CMT1X Biomarkers and Outcome Measures
Open Date: 2021-06-01
Close Date: 2023-05-01
Grant: Close
NIH CMT2A Biomarkers and Outcome Measures
Open Date: 2021-06-01
Close Date: 2023-05-01
Grant: Close
• NIH CMT1B Biomarkers and Outcome Measures
Open Date: 2020-06-01
Close Date: 2022-05-01
Articles (15)
Year:
2025
Background and purpose Charcot−Marie−Tooth disease type 1A (CMT1A) is the most prevalent hereditary neuropathy worldwide and classically has slow nerve conduction velocity (NCV), in most cases below 38 m/s. Two unrelated patients with motor NCVs in the upper limbs above 38 m/s are reported. Method Case report. Results Two genetically confirmed CMT1A patients are presented, from two unrelated families (one of British origin and the other of Brazilian origin). Both individuals had upper limb motor NCVs above 38 m/s, with values ranging from 41.9 to 45 m/s in the median nerve and from 42 to 42.3 m/s in the ulnar nerve. They presented with a very mild phenotype, with CMT Neuropathy Score version 2 (CMTNSv2) of 6 and 5, respectively. In contrast, affected family members within both kinships exhibited a classical phenotype with more severe disease manifestation (CMTNSv2 ranging from 12 to 20) and motor NCVs below 30 m/s. Conclusion These cases, although very rare, highlight the importance of testing PMP22 duplication in patients with intermediate conduction velocities.
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2022
Year:
2022
Year:
2022
Year:
2021
Year:
2021
Year:
2021
Year:
2021
Collaborators (8)
Michael P Lunn
University College London
Matteo Ferla
University of Oxford
Julian D Gillmore
University College London
Diego Kaski
Consultant Neurologist and Senior Lecturer
-
Huw Morris
University College London
Vincent Picher-Martel
Professeur Médecin Adjoint sous octroi
Laval University
Gita Ramdharry
Honorary Associate Professor
UCL Institute of Neurology, University College London
Matilde Laurá
-
Make your next move.
Prepare your application
Review drafts before you send them.